January 4, 2021

Pfizer and BioNTech Speed Up Timeline for Offering Covid-19 Vaccine to Placebo Volunteers

(STAT News) – Pfizer and its partner BioNTech plan to offer their Covid-19 vaccine to any clinical trial volunteer who received placebo by March 1, several months earlier than initially planned. The decision represents the conclusion of a complex and … Read More

December 31, 2020

‘It’s Crazy.’ Upbeat COVID-19 Vaccine News from China and U.K. Leaves Scientists Wanting More Details

(Science) – It’s not clear why the efficacy announced today for the Sinopharm vaccine is lower than the UAE claimed 3 weeks ago. And the paucity of detail in CNBG’s announcement perplexed some scientists. “I think that in America, rightly, … Read More

December 30, 2020

China’s Sinopharm Says Its Coronavirus Vaccine Is 79% Effective

(CNN) – China’s state-owned pharmaceutical giant Sinopharm has announced its coronavirus vaccine is 79.34% effective. Interim analysis of Phase 3 clinical trials show the vaccine is safe and people who received two doses produced high-level antibodies, according to a statement … Read More

December 23, 2020

China’s Sinovac Delays Covid-19 Vaccine Trial Results

(The Wall Street Journal) – hinese firm Sinovac Biotech Ltd. has delayed the announcement of results from late-stage trials of its Covid-19 vaccine to January as it consolidates data from Brazil with test results from Indonesia and Turkey. Brazil, which … Read More

December 23, 2020

Makers of Successful COVID-19 Vaccines Wrestle with Options for Placebo Recipients

(Science) – Now that regulators around the world have begun to issue emergency use authorizations (EUAs) for COVID-19 vaccines—the United States authorized a candidate vaccine from the biotech Moderna on Friday—a theoretical debate that has simmered for months has become … Read More

December 21, 2020

Chinese and Russian Vaccines Remain Unproven–But Desperate Countries Plan to Use Them Anyway

(Washington Post) – In the race to vaccinate the world, China and Russia appear headed to becoming international players, as countries buy up doses and push ahead with approvals even before the release of crucial trial data. Although both countries’ … Read More